Cargando…

Longitudinal Clinical and Cognitive Changes Along the Alzheimer Disease Continuum in Down Syndrome

IMPORTANCE: Alzheimer disease (AD) is the main medical problem in adults with Down syndrome (DS). However, the associations of age, intellectual disability (ID), and clinical status with progression and longitudinal cognitive decline have not been established. OBJECTIVE: To examine clinical progress...

Descripción completa

Detalles Bibliográficos
Autores principales:	Videla, Laura, Benejam, Bessy, Pegueroles, Jordi, Carmona-Iragui, María, Padilla, Concepción, Fernández, Susana, Barroeta, Isabel, Altuna, Miren, Valldeneu, Silvia, Garzón, Diana, Ribas, Laia, Montal, Víctor, Arranz Martínez, Javier, Rozalem Aranha, Mateus, Alcolea, Daniel, Bejanin, Alexandre, Iulita, Maria Florencia, Videla Cés, Sebastià, Blesa, Rafael, Lleó, Alberto, Fortea, Juan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Medical Association 2022
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9356319/ https://www.ncbi.nlm.nih.gov/pubmed/35930282 http://dx.doi.org/10.1001/jamanetworkopen.2022.25573

Ejemplares similares

Neural correlates of episodic memory in adults with Down syndrome and Alzheimer’s disease
por: Benejam, Bessy, et al.
Publicado: (2022)

Diagnosis of prodromal and Alzheimer's disease dementia in adults with Down syndrome using neuropsychological tests
por: Benejam, Bessy, et al.
Publicado: (2020)

VAMP-2 is a surrogate cerebrospinal fluid marker of Alzheimer-related cognitive impairment in adults with Down syndrome
por: Lleó, Alberto, et al.
Publicado: (2021)

Phosphorylated tau181 in plasma as a potential biomarker for Alzheimer’s disease in adults with Down syndrome
por: Lleó, Alberto, et al.
Publicado: (2021)

Association of Apolipoprotein E ɛ4 Allele With Clinical and Multimodal Biomarker Changes of Alzheimer Disease in Adults With Down Syndrome
por: Bejanin, Alexandre, et al.
Publicado: (2021)

Cerebrospinal fluid profile of NPTX2 supports role of Alzheimer’s disease-related inhibitory circuit dysfunction in adults with Down syndrome
por: Belbin, Olivia, et al.
Publicado: (2020)

Association of Alzheimer Disease With Life Expectancy in People With Down Syndrome
por: Iulita, Maria Florencia, et al.
Publicado: (2022)

Association of biological sex with clinical outcomes and biomarkers of Alzheimer’s disease in adults with Down syndrome
por: Iulita, M Florencia, et al.
Publicado: (2023)

Obesity impacts brain metabolism and structure independently of amyloid and tau pathology in healthy elderly
por: Pegueroles, Jordi, et al.
Publicado: (2020)

Evaluation of biochemical and hematological parameters in adults with Down syndrome
por: de Gonzalo-Calvo, David, et al.
Publicado: (2020)

Nerve growth factor (NGF) pathway biomarkers in Down syndrome prior to and after the onset of clinical Alzheimer's disease: A paired CSF and plasma study
por: Pentz, Rowan, et al.
Publicado: (2020)

Clinical and biomarker changes of Alzheimer's disease in adults with Down syndrome: a cross-sectional study
por: Fortea, Juan, et al.
Publicado: (2020)

Plasma glial fibrillary acidic protein and neurofilament light chain for the diagnostic and prognostic evaluation of frontotemporal dementia
por: Zhu, Nuole, et al.
Publicado: (2021)

Correction: Plasma glial fibrillary acidic protein and neurofilament light chain for the diagnostic and prognostic evaluation of frontotemporal dementia
por: Zhu, Nuole, et al.
Publicado: (2023)

Obesity and Alzheimer's disease, does the obesity paradox really exist? A magnetic resonance imaging study
por: Pegueroles, Jordi, et al.
Publicado: (2018)

AMYQ: An index to standardize quantitative amyloid load across PET tracers
por: Pegueroles, Jordi, et al.
Publicado: (2021)

The Aβ1–42/Aβ1–40 ratio in CSF is more strongly associated to tau markers and clinical progression than Aβ1–42 alone
por: Delaby, Constance, et al.
Publicado: (2022)

Feasibility and Long-Term Compliance to Continuous Positive Airway Pressure Treatment in Adults With Down Syndrome, a Genetic Form of Alzheimer’s Disease
por: Giménez, Sandra, et al.
Publicado: (2022)

Weight loss in the healthy elderly might be a non-cognitive sign of preclinical Alzheimer's disease
por: Jimenez, Amanda, et al.
Publicado: (2017)

Monoaminergic impairment in Down syndrome with Alzheimer's disease compared to early-onset Alzheimer's disease
por: Dekker, Alain D., et al.
Publicado: (2017)

The Sant Pau Initiative on Neurodegeneration (SPIN) cohort: A data set for biomarker discovery and validation in neurodegenerative disorders
por: Alcolea, Daniel, et al.
Publicado: (2019)

Challenges associated with biomarker-based classification systems for Alzheimer's disease
por: Illán-Gala, Ignacio, et al.
Publicado: (2018)

Differential levels of Neurofilament Light protein in cerebrospinal fluid in patients with a wide range of neurodegenerative disorders
por: Delaby, C., et al.
Publicado: (2020)

Periodontal disease's contribution to Alzheimer's disease progression in Down syndrome
por: Kamer, Angela R., et al.
Publicado: (2016)

Combination Therapy for Neuropathic Pain: A Review of Recent Evidence
por: Serrano Afonso, Ancor, et al.
Publicado: (2021)

Mechanisms Involved in Epileptogenesis in Alzheimer’s Disease and Their Therapeutic Implications
por: Altuna, Miren, et al.
Publicado: (2022)

DYRK1A and Activity-Dependent Neuroprotective Protein Comparative Diagnosis Interest in Cerebrospinal Fluid and Plasma in the Context of Alzheimer-Related Cognitive Impairment in Down Syndrome Patients
por: Moreau, Manon, et al.
Publicado: (2022)

Agreement of amyloid PET and CSF biomarkers for Alzheimer's disease on Lumipulse
por: Alcolea, Daniel, et al.
Publicado: (2019)

APP‐derived peptides reflect neurodegeneration in frontotemporal dementia
por: Illán‐Gala, Ignacio, et al.
Publicado: (2019)

Evaluation of cerebrospinal fluid levels of synaptic vesicle protein, VAMP-2, across the sporadic Alzheimer’s disease continuum
por: Goossens, Julie, et al.
Publicado: (2023)

APOE-by-sex interactions on brain structure and metabolism in healthy elderly controls
por: Sampedro, Frederic, et al.
Publicado: (2015)

Motor cortex transcriptome reveals microglial key events in amyotrophic lateral sclerosis
por: Dols-Icardo, Oriol, et al.
Publicado: (2020)

Different pattern of CSF glial markers between dementia with Lewy bodies and Alzheimer’s disease
por: Morenas-Rodríguez, Estrella, et al.
Publicado: (2019)

Cortical microstructure in primary progressive aphasia: a multicenter study
por: Illán-Gala, Ignacio, et al.
Publicado: (2022)

Correction: Cortical microstructure in primary progressive aphasia: a multicenter study
por: Illán-Gala, Ignacio, et al.
Publicado: (2023)

Epilepsy in Down Syndrome: A Highly Prevalent Comorbidity
por: Altuna, Miren, et al.
Publicado: (2021)

Pathophysiological Underpinnings of Extra-Motor Neurodegeneration in Amyotrophic Lateral Sclerosis: New Insights From Biomarker Studies
por: Reyes-Leiva, David, et al.
Publicado: (2022)

A new cognitive evaluation battery for Down syndrome and its relevance for clinical trials
por: de Sola, Susana, et al.
Publicado: (2015)

Sleep Disorders in Adults with Down Syndrome
por: Giménez, Sandra, et al.
Publicado: (2021)

Decreased CX3CL1 Levels in the Cerebrospinal Fluid of Patients With Alzheimer’s Disease
por: Perea, Juan R., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_9unnr5ibgercvrj2pegjjo9mbp